ToxStrategies Acquires Suttons Creek

August 13, 2024 –Katy, Texas — ToxStrategies, a leading multidisciplinary scientific consulting firm, today announced the acquisition of Suttons Creek. Founded in 2012 by Steven Badelt, PhD, Suttons Creek offers comprehensive consulting and execution services for combination product development across each phase of the product lifecycle. These product development services include quality, regulatory, human factors and usability engineering, strategy consulting, training and education, and corporate readiness and executive advising. ToxStrategies is a portfolio company of Renovus Capital Partners. Terms of the transaction were not disclosed.

ToxStrategies partnered with Renovus in November 2022 with the goal of expanding its existing client base and developing new end markets. The acquisition of Suttons Creek by ToxStrategies brings together two best-in-class firms within the life sciences industry, with a unified focus on providing integrated teams to solve the multifaceted problems and challenges faced by its clients, particularly in the drug development arena. Steven Badelt will continue to lead Suttons Creek as a Division of ToxStrategies.

Suttons Creek includes a staff of globally experienced, highly specialized consultants with deep knowledge of all aspects of combination product development and deployment through the complex regulatory approval process. They have a proven track record of creating successful pathways to global regulatory approval and commercialization of combination products. Their team of experts has the know-how to integrate the device-related aspects of combination products into any phase of pharmaceutical development and commercialization. With client business goals in mind, Suttons Creek creates adaptive strategies and customized processes for faster entry to the market.

“We are excited to welcome the Suttons Creek engineers, scientists, and regulatory specialists to our growing team of consultants,” said ToxStrategies President Dr. Laurie Couture Haws, PhD, DABT, ATS. “These experts work to assist clients in the pharmaceutical and medical device industries with the safety assessment, regulatory approval, commercialization, and transport of new, life-changing therapies and treatments. The Suttons Creek team expands and complements our current capabilities to include drug and biologic delivery systems. Suttons Creek offers expert-managed services and consulting that align with ToxStrategies’ mission of delivering unparalleled technical excellence to address our clients’ needs, with a spirit of collaboration and passion for advancing science.”

Steven Badelt added, “Suttons Creek started with the goal of providing the best available managed services and consulting on combination products in the pharmaceutical industry. We sought a partner organization that would offer expertise and investment support for scaling while continuing our unwavering commitment to client success…and we found that partner in ToxStrategies! The combination of our enterprises is now fueled by the expertise in scaling provided by Renovus and supported by the culture of ToxStrategies, with their vision of technical excellence and advancing science, as stated by Dr. Haws. This move will allow us to offer a broader portfolio of solutions to clients as we grow to lead the industry in providing managed services for combination products and beyond.”

“ToxStrategies has generated significant momentum over the last year in terms of adding new service offerings to its life sciences practice,” said Jesse Serventi, a founding partner at Renovus Capital Partners. “We are thrilled to welcome Suttons Creek into the fold, bringing deep regulatory expertise to the medical device, pharmaceutical, and combination products industries. We are confident that this acquisition will allow ToxStrategies to deliver even more value to its clients and provide numerous growth opportunities for the company.”